A Long-term Follow-up Study in Participants Who Received CS-101

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Beta-Thalassemia

Interventions

GENETIC

CS-101

Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Trial Locations (1)

RECRUITING

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors

lead

Children's Hospital of Fudan University

OTHER